Cytosorbents (CTSO) Competitors

Cytosorbents (NASDAQ:CTSO) and Accuray (NASDAQ:ARAY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, community ranking, dividends, earnings, analyst recommendations, valuation and risk.

Does the MarketBeat Community favor CTSO or ARAY?

Cytosorbents received 105 more outperform votes than Accuray when rated by MarketBeat users. Likewise, 75.87% of users gave Cytosorbents an outperform vote while only 65.61% of users gave Accuray an outperform vote.

Company	Underperform	Outperform
Cytosorbents	Outperform Votes 437 75.87%	Underperform Votes 139 24.13%
Accuray	Outperform Votes 332 65.61%	Underperform Votes 174 34.39%

Do insiders and institutionals have more ownership in CTSO or ARAY?

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 6.6% of Cytosorbents shares are held by company insiders. Comparatively, 4.2% of Accuray shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the media favor CTSO or ARAY?

In the previous week, Cytosorbents had 3 more articles in the media than Accuray. MarketBeat recorded 6 mentions for Cytosorbents and 3 mentions for Accuray. Accuray's average media sentiment score of 0.43 beat Cytosorbents' score of -0.24 indicating that Accuray is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Accuray	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend CTSO or ARAY?

Cytosorbents currently has a consensus price target of $2.00, indicating a potential upside of 118.36%. Accuray has a consensus price target of $9.00, indicating a potential upside of 391.80%. Given Accuray's higher possible upside, analysts plainly believe Accuray is more favorable than Cytosorbents.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Accuray	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better earnings & valuation, CTSO or ARAY?

Accuray has higher revenue and earnings than Cytosorbents. Accuray is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$33.79M	1.48	-$28.51M	-$0.36	-2.54
Accuray	$444.20M	0.41	-$15.55M	-$0.17	-10.76

Which has more volatility and risk, CTSO or ARAY?

Cytosorbents has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500.

Is CTSO or ARAY more profitable?

Accuray has a net margin of -3.72% compared to Cytosorbents' net margin of -49.47%. Accuray's return on equity of -36.93% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-49.47%	-118.54%	-42.31%
Accuray	-3.72%	-36.93%	-3.52%

Summary

Accuray beats Cytosorbents on 11 of the 18 factors compared between the two stocks.